SLU-PP-332
An investigational small molecule ERR agonist studied as a preclinical exercise mimetic for effects on mitochondrial function, endurance, and fat oxidation.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is SLU-PP-332?
SLU-PP-332 is an investigational small molecule developed by Thomas Burris and colleagues at Saint Louis University as a pan-agonist of the estrogen-related receptor (ERR) family, which includes ERRα, ERRβ, and ERRγ. These nuclear receptors are master regulators of mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism, and are involved in tissue adaptations to exercise. The compound is not a peptide but is included in research catalogs due to its connection to exercise mimetic research and metabolic optimization.
SLU-PP-332 is notable in research because of substantial interest generated by a 2023 publication in Cell Metabolism describing the compound’s effects in mice. The study reported that SLU-PP-332 administration to sedentary mice increased running endurance by approximately 50%, increased fat oxidation, and produced muscle adaptations resembling those seen with endurance training. It is important to emphasize that SLU-PP-332 is an early-stage investigational compound — no human clinical trials have been conducted, and the published research consists primarily of preclinical mouse studies. Human safety, pharmacokinetics, and efficacy are uncharacterized.
Mechanism of action
SLU-PP-332’s mechanisms of action have been investigated across multiple pathways:
- Pan-ERR agonism: The compound activates all three estrogen-related receptor subtypes (ERRα, ERRβ, ERRγ), which are nuclear receptors regulating mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism.
- Mitochondrial biogenesis: Research has documented increases in mitochondrial number and function in muscle tissue, with effects on the expression of genes involved in mitochondrial protein synthesis and function.
- Fat oxidation enhancement: Studies have reported increased fatty acid oxidation in muscle tissue, with effects on the molecular machinery of lipid metabolism in skeletal muscle.
- Exercise adaptation mimicry: Effects produced in sedentary animals resemble adaptations normally requiring endurance training, including improvements in running capacity and muscle metabolic profile.
- Body composition effects: Some reports indicate reduced body weight and fat mass in obese mouse models, with implications for metabolic disease research.
These pathways are characterized primarily in mouse models with limited additional preclinical data.
Research applications
SLU-PP-332 has been investigated across several research domains, with the most active areas including:
- Exercise mimetic research: The primary research application examines whether SLU-PP-332 can produce exercise-like adaptations in sedentary models, with mouse studies reporting approximately 50% increases in running endurance and substantial improvements in muscle metabolic profile.
- Obesity and metabolic disease research: Studies have examined effects on body weight, fat mass, and metabolic parameters in obese mouse models, with research interest in applications for metabolic syndrome and related conditions.
- Cardiac research: Research has examined ERR agonism effects in cardiac tissue, with studies suggesting potential applications in heart failure and cardiac mitochondrial dysfunction.
- Aging research: ERR signaling declines with age in parallel with mitochondrial function, and research has examined whether ERR agonism could affect aging-related mitochondrial decline.
- Nuclear receptor pharmacology research: SLU-PP-332 serves as a research tool for studying ERR biology and the effects of pan-ERR agonism on tissue physiology, contributing to mechanistic understanding of these nuclear receptors.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
Specific storage and reconstitution protocols depend on the supplier and form. Typically, lyophilized small molecule research compounds are stored at -20°C protected from light, with reconstitution per supplier instructions. The compound’s stability characteristics are not as well-established as for compounds with longer research histories.
Once reconstituted, solutions should be stored refrigerated at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can accelerate degradation.
Visual inspection should be performed before each use. The reconstituted solution should be clear and colorless. Reject any solution that appears cloudy, discolored, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.